Healthcare provider profile · identity verified

Daniel Allen Huie, MD

Family Practice · MENLO PARK, CA · NPI 1295794725

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	361	101
Amlodipine Besylate	Amlodipine Besylate	239	70
Levothyroxine Sodium	Levothyroxine Sodium	148	41
Tamsulosin Hcl	Tamsulosin Hcl	146	45
Losartan Potassium	Losartan Potassium	145	41
Ezetimibe	Ezetimibe	143	39
Rosuvastatin Calcium	Rosuvastatin Calcium	124	40
Olmesartan Medoxomil	Olmesartan Medoxomil	116	35
Famotidine	Famotidine	109	34
Gabapentin	Gabapentin	89	23
Metoprolol Succinate	Metoprolol Succinate	76	26
Metformin Hcl Er	Metformin Hcl	72	22
Zolpidem Tartrate	Zolpidem Tartrate	69	22
Montelukast Sodium	Montelukast Sodium	68	24
Trazodone Hcl	Trazodone Hcl	68	16
Finasteride	Finasteride	67	19
Simvastatin	Simvastatin	66	17
Allopurinol	Allopurinol	59	14
Hydrochlorothiazide	Hydrochlorothiazide	58	19
Omeprazole	Omeprazole	58	19
Ramipril	Ramipril	54	14
Clonazepam	Clonazepam	52	11
Lisinopril	Lisinopril	49	14
Paxlovid	Nirmatrelvir/Ritonavir	46	42
Doxycycline Hyclate	Doxycycline Hyclate	43	36
Synthroid	Levothyroxine Sodium	43	14
Citalopram Hbr	Citalopram Hydrobromide	40	suppressed
Ozempic	Semaglutide	40	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	36	15
Escitalopram Oxalate	Escitalopram Oxalate	33	suppressed
Metformin Hcl	Metformin Hcl	33	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	31	suppressed
Lorazepam	Lorazepam	29	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	28	suppressed
Eliquis	Apixaban	28	suppressed
Sertraline Hcl	Sertraline Hcl	28	suppressed
Valsartan	Valsartan	28	suppressed
Pravastatin Sodium	Pravastatin Sodium	26	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	26	suppressed
Fluticasone Propionate	Fluticasone Propionate	25	suppressed
Carvedilol	Carvedilol	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	15
Trulicity	Dulaglutide	24	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	23	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	21	suppressed
Colchicine	Colchicine	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Furosemide	Furosemide	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Duloxetine Hcl	Duloxetine Hcl	17	suppressed
Testosterone	Testosterone	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	12
Atenolol	Atenolol	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Prednisone	Prednisone	16	14
Dexlansoprazole Dr	Dexlansoprazole	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Midodrine Hcl	Midodrine Hcl	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	12
Edarbi	Azilsartan Medoxomil	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Alprazolam	Alprazolam	13	suppressed
Fentanyl	Fentanyl	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	11
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Azithromycin	Azithromycin	12	suppressed
Carisoprodol	Carisoprodol	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed
Raloxifene Hcl	Raloxifene Hcl	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error